Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LCAT | P04180 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461453 | 0.89 | ATM (0.55) | HTTALDH1A1ATMLCATPHGDH | |
| SCHEMBL18711350 | 0.74 | ATM (0.52) | HTTALDH1A1ATMPHGDHMEN1 | |
| SCHEMBL12042000 | 0.72 | HTT (0.48) | HTTALDH1A1ATMLCATPHGDH | |
| SCHEMBL2200037 | 0.72 | ATM (0.56) | HTTALDH1A1ATMLCATPHGDH | |
| SCHEMBL18702081 | 0.71 | ATM (0.50) | HTTALDH1A1ATMPHGDHMEN1 | |
| SCHEMBL414029 | 0.71 | HTT (0.47) | HTTALDH1A1ATMLCATPHGDH | |
| SCHEMBL2119090 | 0.70 | ATM (0.52) | HTTALDH1A1ATMPHGDHMEN1 | |
| SCHEMBL12042057 | 0.70 | HTT (0.46) | HTTALDH1A1ATMLCATPHGDH | |
| SCHEMBL13447349 | 0.70 | ATM (0.59) | HTTALDH1A1ATMPHGDHMEN1 | |
| SCHEMBL15025447 | 0.70 | ATM (0.59) | HTTALDH1A1ATMLCATPHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101137363-B | [4- (heteroaryl) piperazin-1-yl ] - (2, 5-substituted-phenyl) methanone derivatives as glycine transporter 1(GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-1838308-B1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| CN-101137363-A | [ 4- (heteroaryl) piperazin-1-yl ] - (2, 5-substituted-phenyl) methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | CN | disclosed |
| EP-1838308-A1 | [4-(HETEROARYL)PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-7220744-B2 | Monocyclic substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | US | disclosed |
| WO-2006072436-A1 | [4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167009-A1 | Monocyclic substituted phenyl methanones | SLC1A2, SULT2A1, SLC6A5 | HTT 520/4885ALDH1A1 744/4885ATM 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.